Blood-Based Alzheimer's Diagnostics | Diagnostics Market Intelligence

Description

List of Tables

The economics of Alzheimer's treatment in Japan now run through a blood draw. Disease-modifying therapies require confirmed amyloid pathology before the first infusion, and the confirmation options, PET imaging and CSF testing, are capacity-limited, invasive, or both. Blood-based biomarkers promise to remove that bottleneck, and the market has moved quickly: the first FDA-cleared blood test for Alzheimer's arrived in 2025, and in February 2026 Sysmex and Fujirebio formed an exclusive sales collaboration that places two Japanese companies at the center of their home market's diagnostic transition.

What remains unresolved is payment. Japan's NHI system has not yet established a reimbursement pathway for blood-based Alzheimer's biomarkers, and without one, testing cannot scale to the population that therapy eligibility would imply. The gatekeeping function of these tests, they determine who enters a treatment pathway with substantial downstream costs, gives the reimbursement decision unusual weight. Platform competition is also live: automated immunoassay systems from Sysmex, Fujirebio, Roche, Abbott, and Siemens contend with ultra-sensitive research-grade platforms from Quanterix, mass-spectrometry approaches from C2N and Shimadzu, and community-oriented assays such as ALZpath, each with different performance claims, installed bases, and regulatory strategies.

This report maps the field end to end. It explains the biomarker science, pTau217, pTau181, amyloid ratios, and NfL, and the clinical-validation frameworks regulators apply; reconstructs the regulatory pathway from the FDA's first clearance through PMDA review options; and analyzes the NHI price-formation process that will determine commercial reality in Japan. It profiles the Sysmex-Fujirebio collaboration in detail, maps the reference-laboratory channel through SRL and BML, and covers the international landscape across the US, EU5, and China, where laboratory-developed-test rules, IVDR, and reimbursement decisions are moving on different clocks.

The report is written for IVD manufacturers planning Japan entry or defense, reference laboratories building neurology menus, pharma companion-diagnostics teams whose therapy uptake depends on testing capacity, and investors tracking the diagnostics layer of the Alzheimer's market. Each platform chapter follows the same structure so that technical, regulatory, and commercial positions can be compared directly.

Scope and Coverage

The report covers blood-based Alzheimer's biomarker platforms, regulatory pathways, and reimbursement mechanics across the US, EU5, Japan, and China, including immunoassay, mass-spectrometry, and single-molecule technologies and the reference-laboratory channel. Amyloid PET and CSF testing are covered as comparator modalities. Therapy markets are covered in companion reports.

Report Highlights

Biomarker science and clinical-validation frameworks for pTau217, amyloid ratios, and NfL
Sysmex-Fujirebio exclusive sales collaboration: structure and market implications
Platform-by-platform competitive comparison across immunoassay, MS, and single-molecule technologies
PMDA, FDA, and IVDR regulatory pathways for Alzheimer's blood tests
NHI price-formation process and the open reimbursement decision
Reference-laboratory channel analysis: SRL, BML, and hospital laboratories

Product Code: JPH-007

Table of Content

1. Executive Summary

2. Blood-Based Alzheimer's Diagnostics: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Sysmex (JP) - HISCL automated immunoassay platform; exclusive Fujirebio sales collaboration from 2026
Fujirebio (JP) - Lumipulse pTau217 and NfL assays; first FDA-cleared blood AD test (2025)
Roche (CH) - Elecsys pTau217 and amyloid panel on cobas platforms
Quanterix (US) - Simoa ultra-sensitive pTau217 and NfL assays for research and clinical use
C2N Diagnostics (US) - PrecivityAD mass-spectrometry amyloid and pTau217 tests
Fujifilm (JP) - reagent and diagnostics interests via Fujifilm Wako Pure Chemical
Abbott (US) - Alinity-based pTau217 development program
Siemens Healthineers (DE) - Atellica platform neurology-marker menu development
Beckman Coulter (US) - Access platform neuro-marker R&D under Danaher
Shimadzu (JP) - MALDI-MS blood amyloid technology from the Koichi Tanaka research program
ALZpath (US) - pTau217 clinical assay for community use
SRL (JP) - reference-lab channel for specialized AD testing under H.U. Group
BML (JP) - reference-lab channel for biomarker testing

Product Code: JPH-007

List of Tables

Table 1. Alzheimer's biomarker framework: AT(N) classification and the role of blood-based markers
Table 2. pTau217, pTau181, amyloid-beta ratios, and NfL: analyte definitions and measurement requirements
Table 3. Analytical-technology taxonomy: chemiluminescent immunoassay, Simoa, mass spectrometry, and MALDI approaches
Table 4. Milestones in blood-based Alzheimer's diagnostics by year
Table 5. Target testing populations: memory-clinic, primary-care, and screening frameworks
Table 6. Position of blood tests within the Alzheimer's diagnostic pathway
Table 7. Comparator modalities: amyloid PET and CSF testing infrastructure in Japan
Table 8. Pre-analytical and sample-handling requirements across platforms
Table 9. Japanese memory-clinic and dementia-specialist network structure
Table 10. Current testing practice: how eligibility confirmation is performed today
Table 11. Laboratory workflow structures in hospital and reference-lab settings
Table 12. Ordering and interpretation practice: physician decision points
Table 13. Quality-assurance and standardization frameworks for Alzheimer's biomarkers
Table 14. Guideline positions on blood-based biomarkers from Japanese and international societies
Table 15. Fujirebio Lumipulse pTau217 and NfL assays: platform structure and FDA clearance history
Table 16. Sysmex HISCL amyloid and tau assay menu and installed base
Table 17. Roche Elecsys pTau217 and amyloid panel development program
Table 18. Quanterix Simoa ultra-sensitive assay portfolio and research-to-clinic pathway
Table 19. C2N PrecivityAD mass-spectrometry test structure
Table 20. Shimadzu MALDI-MS blood amyloid technology from the Tanaka research program
Table 21. Abbott Alinity and Siemens Atellica neurology-marker development programs
Table 22. Beckman Coulter Access platform neuro-marker R&D
Table 23. ALZpath pTau217 clinical assay and community-testing model
Table 24. Fujifilm Wako Pure Chemical reagent interests in the biomarker supply chain
Table 25. Platform development roadmap comparison across vendors
Table 26. FDA pathway for blood-based Alzheimer's tests: the 2025 clearance precedent
Table 27. PMDA review options for in-vitro diagnostics with therapy-gatekeeping claims
Table 28. EU IVDR classification and its effect on Alzheimer's assay availability
Table 29. China NMPA pathway for neurology biomarker assays
Table 30. Clinical-validation evidence expectations: reference standards and concordance frameworks
Table 31. Laboratory-developed-test regulation and its effect on service-based models
Table 32. NHI price-formation process for novel in-vitro diagnostics
Table 33. C1/C2/C3 classification considerations for Alzheimer's blood tests
Table 34. Reimbursement linkage between biomarker testing and therapy eligibility
Table 35. US reimbursement structures: Medicare and commercial coverage for Alzheimer's blood tests
Table 36. EU5 reimbursement and procurement environments for neurology biomarkers
Table 37. China payment environment for advanced IVD testing
Table 38. Reference-laboratory channel: SRL structure under H.U. Group
Table 39. Reference-laboratory channel: BML and competing laboratory networks
Table 40. Hospital-laboratory adoption pathway for automated assays
Table 41. Sysmex: diagnostics franchise structure and the Fujirebio collaboration
Table 42. Fujirebio: neurology-assay portfolio and partner network
Table 43. Roche Diagnostics: Elecsys strategy in neurology
Table 44. Quanterix, C2N, and ALZpath: specialist positioning
Table 45. Shimadzu: MALDI-MS platform strategy
Table 46. Vendor positioning map: installed base, assay menu, and regulatory status
Table 47. Unmet needs: the reimbursement gap and its consequences for access
Table 48. Entry and expansion options for IVD companies in Japan
Table 49. Report methodology: source hierarchy, platform-audit approach, and cut-off dates
Table 50. Glossary of analytes, platforms, and regulatory terms

List of Figures

Figure 1. AT(N) biomarker framework and the position of blood-based markers
Figure 2. Analyte map: pTau217, pTau181, amyloid ratios, and NfL
Figure 3. Analytical-technology comparison schematic
Figure 4. Timeline of blood-based Alzheimer's diagnostics development
Figure 5. Testing-population funnel: memory clinic, primary care, and screening
Figure 6. Diagnostic pathway map with blood-test insertion points
Figure 7. Comparator-modality infrastructure: PET and CSF in Japan
Figure 8. Pre-analytical workflow requirements diagram
Figure 9. Memory-clinic network structure in Japan
Figure 10. Current eligibility-confirmation practice flow
Figure 11. Hospital and reference-lab workflow structures
Figure 12. Physician ordering and interpretation decision points
Figure 13. Quality-assurance and standardization architecture
Figure 14. Guideline-position landscape across societies
Figure 15. Lumipulse platform structure and clearance timeline
Figure 16. HISCL assay menu and installed-base structure
Figure 17. Elecsys neurology-panel development schematic
Figure 18. Simoa technology and research-to-clinic pathway
Figure 19. PrecivityAD mass-spectrometry workflow
Figure 20. Shimadzu MALDI-MS technology schematic
Figure 21. Alinity and Atellica development-program map
Figure 22. Beckman Coulter neuro-marker R&D structure
Figure 23. ALZpath community-testing model diagram
Figure 24. Reagent supply-chain interests in the biomarker field
Figure 25. Vendor roadmap comparison timeline
Figure 26. FDA pathway flow: the 2025 clearance precedent
Figure 27. PMDA review pathway for gatekeeping IVDs
Figure 28. IVDR classification impact flow for Alzheimer's assays
Figure 29. NMPA pathway flow for neurology biomarkers
Figure 30. Clinical-validation evidence ladder
Figure 31. LDT regulation and service-model decision points
Figure 32. NHI price-formation flow for novel IVDs
Figure 33. C1/C2/C3 classification decision tree
Figure 34. Testing-to-therapy reimbursement linkage diagram
Figure 35. US coverage architecture for Alzheimer's blood tests
Figure 36. EU5 reimbursement and procurement map
Figure 37. China payment environment map
Figure 38. SRL channel structure under H.U. Group
Figure 39. BML and competing laboratory network structure
Figure 40. Hospital-laboratory adoption pathway
Figure 41. Sysmex franchise structure and collaboration diagram
Figure 42. Fujirebio portfolio and partner network map
Figure 43. Roche neurology strategy schematic
Figure 44. Specialist-vendor positioning map
Figure 45. Shimadzu platform strategy diagram
Figure 46. Vendor positioning matrix: base, menu, and regulatory status
Figure 47. Reimbursement-gap consequence map for access
Figure 48. Japan entry and expansion route map for IVD companies
Figure 49. Methodology flow: sources, platform audit, and cut-off dates
Figure 50. Data cut-off and update cadence schematic

Blood-Based Alzheimer's Diagnostics | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Blood-Based Alzheimer's Diagnostics: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures